Abstract
Effects of antagonists of the NPY-2 receptor, semaglutide, PYY3-36, and empagliflozin on metabolic dysfunction-associated steatotic liver disease in diet-induced obese rats
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have